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Background: Hypoxia imaging is a promising tool for targeted therapy but the links between imaging features and underlying
molecular characteristics of the tumour have not been investigated. The aim of this study was to compare hypoxia biomarkers and
gene expression in oropharyngeal squamous cell carcinoma (OPSCC) diagnostic biopsies with hypoxia imaged with 64Cu-ATSM
PET/CT.
Methods: 64Cu-ATSM imaging, molecular and clinical data were obtained for 15 patients. Primary tumour SUVmax, tumour
to muscle ratio (TMR) and hypoxic volume were tested for association with reported hypoxia gene signatures in
diagnostic biopsies. A putative gene signature for hypoxia in OPSCCs (hypoxic volume-associated gene signature (HVS))
was derived.
Results: Hypoxic volume was significantly associated with a reported hypoxia gene signature (rho¼ 0.57, P¼ 0.045), but SUVmax
and TMR were not. Immunohistochemical staining with the hypoxia marker carbonic anhydrase 9 (CA9) was associated with a gene
expression hypoxia response (rho¼ 0.63, P¼ 0.01). Sixteen genes were positively and five genes negatively associated with
hypoxic volume (adjusted Po0.1; eight genes had adjusted Po0.05; HVS). This signature was associated with inferior 3-year
progression-free survival (HR¼ 1.5 (1.0–2.2), P¼ 0.047) in an independent patient cohort.
Conclusions: 64Cu-ATSM-defined hypoxic volume was associated with underlying hypoxia gene expression response. A 21-
gene signature derived from hypoxic volume from patients with OPSCCs in our study may be linked to progression-free
survival.
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Hypoxia has been extensively investigated in head and neck
squamous cell carcinoma (HNSCC) and the association with poor
outcome is well known (Nordsmark et al, 2005). A number of
therapeutic interventions can target global or focal hypoxia in
tumours (Rischin et al, 2010; Hendrickson et al, 2011); however,
the selection of patients with hypoxic tumours who would benefit
from these interventions has been the major limiting factor for
translation into clinical practice.
Accurate detection and quantification of hypoxic tumours is
essential to identify patients who have aggressive, treatment-
resistant disease. Various methods have been investigated but with
inconsistent and sometimes conflicting results, lacking the
sensitivity and specificity needed for clinical utility (Aebersold
et al, 2001; Overgaard et al, 2005). Hypoxic gene expression
signatures from biopsy samples could have predictive value
(Winter et al, 2007; Toustrup et al, 2011) but are not able
to quantify hypoxia or provide information on its spatial
distribution within tumours. Combining hypoxic gene signatures
and 64Cu-ATSM PET imaging biomarkers may enable a more
comprehensive assessment of the hypoxic status of tumours.
64Cu-ATSM is a PET radiotracer that has been shown to
accumulate in hypoxic and other conditions of mitochondrial
dysfunction (Lewis et al, 1999; Donnelly et al, 2012). Although the
exact mechanism has not been elucidated and uptake may be
dependent on cell or tumour type, clinical studies have clearly
demonstrated the potential as an imaging biomarker that warrants
further investigation, especially in HNSCC, with clear advantages
over the nitroimidazole-based hypoxia tracers (Minagawa et al,
2011; Grassi et al, 2014; Sato et al, 2014).
Our study hypothesis was that hypoxia gene signatures from
diagnostic FFPE biopsy samples would be associated with uptake of
64Cu-ATSM in patients with oropharyngeal squamous cell
carcinoma (OPSCC), and a signature could be developed to
identify patients with OPSCC who would benefit from further
investigation with hypoxia imaging. This would, in turn, provide
more information on the level and distribution of hypoxic regions,
which could potentially guide treatment.
MATERIALS AND METHODS
Patients. Fifteen patients with newly diagnosed histologically
proven stages III–IV squamous cell carcinoma of the oropharynx
to be treated with standard radical concomitant chemoradiation
were prospectively recruited as part of an initial pilot phase of the
study. HPV status was determined by p16 IHC and by in situ
hybridisation for high-risk subtype DNA. Patients received a static
64Cu-ATSM PET/CT scan of the head and neck approximately 1
week prior to the start of their treatment. Time between biopsy and
imaging was recorded (Table 1, Supplementary Figure S7). On
inspection of clinical follow-up, there was one reported death (not
disease-specific) and all other patients so far have no recurrence
(median time to follow-up, 24 months). Research Ethics Commit-
tee approval was obtained for the study (reference 12/LO/1123)
and all patients gave written and voluntary consent.
Image acquisition and analysis. Detailed methods for image
acquisition and analysis are provided as Supplementary
Information. In summary, patients were injected with 545±27
(range 486–577) MBq of 64Cu-ATSM followed by an uptake period
of 60min. The first patient acquisition was performed on a GE
Discovery VCT PET/CT scanner (General Electric Medical
Systems, Waukesha, WI, USA). All subsequent patients were
imaged on the GE Discovery 710 PET/CT scanner. The 64Cu-
ATSM PET/CT images were interpreted by a nuclear medicine
physician and clinical oncologist using Hermes Hybrid Viewer
version 2.2C (Hermes Medical Solutions, Stockholm, Sweden).
PET uptake was assessed semi-quantitatively using standardised
uptake values (SUV) normalised to patient body weight deter-
mined using the following Equation:
SUVbw¼ 64Cu-ATSM activity concentration measured in the
tumour (Bq cc 1) (patient body weight (kg)/injected activity of
64Cu-ATSM (Bq) decay corrected to the time of
injection) 1000 g cc 1.
Visible lesions on PET with uptake higher than background
muscle uptake were considered hypoxic. Background uptake
was evaluated by placing fixed 2.5 cm spheres over bilateral
posterior neck muscles on the CT images to guide correct
positioning, copying the spheres onto the PET images and
calculating the average SUVmean. Regions of interest (ROIs) were
outlined in multiple planes using a set zoom, SUV scaling and
colour scale. An initial region was drawn using an automatic
segmentation seeded region growing tool on each scan slice and
manually edited. The seeded region growing tool starts with a seed
pixel within the tumour and then adds pixels to the region in all
directions. The operator determined the extent of pixel expansion
and final region outlined. ROIs were then summed to create a
volume or the hypoxic volume. For each primary tumour SUVmax,
tumour to muscle ratio (TMR), tumour SUVmean and hypoxic
volume were measured. TMR was determined by the ratio of
tumour SUVmax to the average SUVmean of the posterior neck
muscles.
Immunohistochemistry (IHC), RNA extraction, sequencing and
analysis. Diagnostic biopsy slides were reviewed by a head and
neck pathologist to confirm the diagnosis, and the tumour outline
was marked on the slide without further selection. Sections from
FFPE tumour blocks were placed onto slides for IHC staining for
carbonic anhydrase 9 (CA9), an endogenous marker for hypoxia,
as previously described (Watson et al, 2003). Blocks were then
scored with a surgical blade to correspond with the tumour regions
on the slides. Ten-micrometer-thick sections of the tumour area
were cut on a microtome (minimum 10 sections, minimum
tumour area 100mm2) and sent to BGI (BGI TechSolutions,
Wuhan, China). BGI performed RNA extraction, RNA-sequencing
(seq) and small RNA-seq (Illumina HiSeq 2000, Illumina Inc., San
Diego, CA, USA) and filtered the reads to remove adaptors and
low-quality reads. RNA-seq reads aligned to reference genome
(hg19; BWA v0.7.10-r789) were obtained from BGI and read
counts per gene were enumerated using htseq-count (HTSeq
v0.6.1p1 (Anders et al, 2015); union of exons). Small RNA reads
were obtained from BGI and aligned to microRNA (miRNA)
mature sequences (MirBase v21 (Kozomara and Griffiths-Jones,
2011) using bowtie2 v2.2.5 (Langmead and Salzberg, 2012) with
local alignment (–local –a). Read counts per miRNA were
enumerated using reads that were uniquely mapped among
reported alignments. Differential expression analyses from count
data and read count normalisation (rlog-transform) for visualisa-
tion and clustering were performed using DESeq2 v1.6.3 (Love
et al, 2014). Differential expression analysis of HPV status was
perfomed using DESeq2 with HPV status as the co-variable. Genes
associated with hypoxic volume were identified using DESeq2 with
hypoxic volume as a continuous co-variable. Gene set enrichment
and leading edge analysis (GSEA v2.2.2 (Subramanian et al, 2005);
preranked tool; minimum set size¼ 5; 1000 permutations) was
performed on genes preranked by fold-change (per unit increase
of hypoxic volume) and filtered for coverage (baseMean 4200).
Gene sets with names containing the phrase ‘hypoxia’, ‘HIF1’ or
‘HIF2’ were preselected from all MSigDB curated gene sets
(c2.all.v5.1.symbols.gmt (Subramanian et al, 2005)). Gene signa-
ture scores were estimated from normalised (rlog-transformed)
read counts using a weighted sum of Z-scores for each gene in the
respective gene list, with weights (þ 1,  1) according to the
direction of expression in the original gene signature.
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Analysis of external gene expression data sets. The following
series were retrieved from the Gene Expression Omnibus (an
international public genomics data repository): GSE686 (Chung
et al, 2004) and GSE65858 (Wichmann et al, 2015). Follow-up
information about progression-free survival (GSE65858) was
obtained from GEO, and follow-up information about recur-
rence-free survival (GSE65858) was obtained from the original
publication (Chung et al, 2004). A set of predefined exploratory
analyses of follow-up were performed. Kaplan–Meier plots were
used to inspect the hypoxic volume signature score by upper
quartile, interquartile and lower quartile of the score values,
samples in the upper quartile vs all other samples and samples in
the lower quartile vs all other samples. After inspection of the
Kaplan–Meier plots, exploratory log-rank tests were performed for
3-year follow-up and for the whole follow-up period, and hazard
ratios were fitted to the same time periods using univariable Cox
proportional hazards models.
Statistical analysis. Mann–Whitney U-tests, Kaplan–Meier plots,
log-rank tests and Cox proportional hazard model fits were
performed in the R environment, v3.1.2 and ‘survival’ package
v2.38 (R Core Team, 2014). Exact Wilcoxon–Mann–Whitney tests
were performed using the ‘coin’ package v1.1-2. Cox model
P-values report the Wald test. Unless otherwise stated, two-tailed
tests are reported. Po0.05 was considered to be statistically
significant.
RESULTS
Patient characteristics are summarised in Table 1. There were no
immediate or late adverse reactions after tracer injection. Uptake
was detected in all 15 primary tumours on 64Cu-ATSM PET scans
(Figure 1A). Two patients had diagnostic tonsillectomies at
diagnosis but uptake was seen in the residual disease. The mean
SUVmax for all 15 patients was 3.32±0.85 (range 2.12–4.85) and
the mean TMR was 4.51±1.82 (range 1.84–9.00; Table 1). SUVmax
and TMR were not significantly different between HPV-positive
and HPV-negative patients. Tonsillectomy patients were excluded
from analyses using hypoxic volume and SUVmean.
The mean hypoxic volume in 13 primary tumours was
12.54 cm3±11.53 (range 0.68–36.89) and the mean SUVmean was
2.34±0.45 (range 1.71–3.11; Table 1). Supplementary Figure S1
demonstrates the examples of hypoxic volume delineation.
Increased uptake was detected in 22 lymph nodes on 64Cu-ATSM
PET scans out of 31 abnormal lymph nodes reported on CT
imaging. Lymph node uptake appeared visually to be more
heterogeneous than uptake in the primary tumour, especially in
large nodes, which showed uptake in the periphery with central
regions of no uptake, likely secondary to necrosis (Supplementary
Figure S2). In general, the uptake in the nodes was lower than the
primary. The mean SUVmax of the nodes was 2.43±0.93 (range
1.39–5.80) and the mean TMR 3.29±2.41 (range 1.35–13.18)
(Supplementary Table S1).
The differential gene expression between HPV-positive and
HPV-negative samples were compared with previously published
signatures (Pyeon et al, 2007; Keck et al, 2015) as an initial screen
to assess the RNA sequencing from FFPE samples (Supplementary
Figure S3). Overall, the pattern of gene expression profiles in our
HPV-positive vs HPV-negative samples were readily distinguish-
able and consistent with previous studies. There was no difference
in hypoxic volume, TMR or SUVmax between HPV-positive and
HPV-negative samples.
To establish whether RNA-seq data from the diagnostic biosies
could report gene expression responses to hypoxia, we initially
compared the gene expression of our samples with two different
published hypoxia-associated signatures that have been used to
assess hypoxia: a signature comprising genes regulated by
hypoxia in head and neck cancers (Winter et al, 2007) and the
15-gene hypoxia classifier (Sorensen et al, 2015). There was high
correlation between the two different signatures in our samples
(Supplementary Figure S4C). Hypoxic volume was significantly
associated with both the 15-gene hypoxia classifier (P¼ 0.045;
Spearman’s rho¼ 0.57, two-tailed test, Figure 1D) and the gene list
by Winter et al (P¼ 0.05; Spearman’s rho¼ 0.56, two-tailed test).
SUVmax and TMR were not significantly associated with these
hypoxia signatures; on inspection, four patient samples exhibited
low scores for the 15-gene hypoxia signature but had among the
highest values of SUVmax and TMR (Figure 1D). There were no
significant differences in baseline characteristics between this
‘subgroup’ and the other samples, and these patients were among
the oldest in the study (Mann–Whitney U, W¼ 3, P¼ 0.02).
To verify that hypoxic imaging volume and RNAseq-derived
hypoxia gene expression response were associated with hypoxia in
Table 1. Patient baseline characteristics and uptake values
Study ID Gender Age T stage N stage HPV status SUVmax TMR
Hypoxic volume
(cm3)
SUVmean
Time, biopsy to
imaging (days)
1 Female 51 2 2b Negative 2.57 2.64 9.78 1.96 21
4 Male 60 3 0 Positive 3.61 6.07 29.58 2.45 18
8 Male 71 4 2b Negative 3.96 9.00 5.60 2.46 38
9 Male 54 2 2b Positive 2.67 3.63 35
10 Male 46 4 0 Positive 3.14 3.74 6.31 2.02 34
11 Female 61 2 2a Positive 2.99 3.23 18
12 Male 64 2 2b Positive 4.35 5.61 10.76 3.11 41
13 Male 59 3 1 Positive 3.83 5.36 36.89 2.61 22
14 Male 47 3 2b Positive 3.34 5.91 7.55 2.27 24
15 Male 44 2 2c Negative 4.85 4.71 21.66 2.94 45
16 Male 66 3 2b Negative 3.75 5.00 23.01 2.58 13
17 Male 56 2 2a Positive 2.34 2.91 2.15 1.90 22
18 Male 69 1 2b Negative 2.12 2.83 0.68 1.71 30
19 Male 64 2 1 Positive 4.21 5.10 7.51 2.68 18
20 Female 60 1 2b Positive 2.13 1.84 1.49 1.77 25
Abbreviations: HPV, human papilloma virus; SUV, standardised uptake values; TMR, tumour to mucle ratio. TMR is the ratio of SUVmax to average SUVmean of bilateral posterior neck muscle.
Hypoxic volume and SUVmean are excluded for tonsillectomy patients (Study IDs 9 and 11).
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patient tumours, CA9 protein IHC, a marker for hypoxia, was
performed on biopsy samples. Among the image features, hypoxic
volume showed a positive trend with CA9 IHC scores (Mann–
Whitney U one-tailed, threshold median of hypoxic volume,
P¼ 0.06 (Figure 1B and Supplementary Figure S4A); Spearman’s
rho¼ 0.43, P¼ 0.15 (Supplementary Figure S4A)). SUVmax and
TMR were not associated with CA9 (Figure 1B and Supplementary
Figure S4A). Furthermore, the 15-gene hypoxia classifier score was
significantly associated with CA9 IHC scores (Spearman’s
rho¼ 0.63, P¼ 0.01 (Supplementary Figure S4B)). Genes ranked
according to association with hypoxic volume were found
to be enriched for previously curated hypoxia-associated gene sets
with expression response to hypoxia or downstream of hypoxia-
inducible factor 1 (HIF-1; Supplementary Table S2, Supplementary
Figure S5).
The 15-gene hypoxia classifier (Sorensen et al, 2015) was
originally derived and tested in multiple cancer types and may
represent hypoxia gene expression responses that are commonly
found across differing tumour types (Winter et al, 2007; Sorensen
et al, 2015). We hypothesised that alternative gene signatures could
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Figure 1. 64Cu-ATSM PET imaging and association with CA9 immunohistochemical staining and a hypoxia gene expression response in
disgnostic biopsies. (A–B) Example images of 64Cu-ATSM PET (left) and fused PET/CT (right) scans. (A) Patient with T2N2b left base of tongue
SCC, with Cu-ATSM uptake in the primary but no uptake in left level II neck node. (B) Patient with T3N1 left tonsil SCC with high uptake in primary.
(C) Immunohistochemistry staining of hypoxia biomarker CA9 vs each image feature. ‘High’ is defined as values greater than the median value.
(D) Scatterplots of 64Cu-ATSM imaging parameters vs the previously reported Sorensen2015 hypoxia classifier. Hypoxic volume, TMR and SUVmax
plotted against the 15-gene hypoxia classifier. A significant positive correlation is observed between the hypoxia score and hypoxic volume but
not TMR or SUVmax. Red points indicate samples with low hypoxia score but high SUVmax. Samples from patients who had diagnostic
tonsillectomies (Study IDs 9 and 11) were excluded as a hypoxic volume could not be determined.
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accurately evaluate the hypoxic phenotypes in OPSCCs. We used
the 64Cu-ATSM hypoxic volume together with mRNA expression
from biopsy samples to identify a gene signature for hypoxic
imaging phenotypes in OPSCCs. Hypoxic volume was significantly
associated with increased expression of 16 genes and decreased
expression of 5 genes (hypoxic volume-associated gene signature
(HVS)) (Figure 2A, Supplementary Table S3). Two genes over-
lapped with the 15-gene hypoxia classifier, LOX and PFKFB3. On
inspection, there was concordance between the hypoxic volume-
associated gene signature and expression of the 15-gene hypoxia
classifier (Figure 2A). The HVS was more highly correlated with
each of the image features (hypoxic volume, TMR and SUVmax)
than the 15-gene hypoxia classifier, but only the hypoxic volume
was significantly correlated with HVS (hypoxic volume: rho¼ 0.89,
Po10 4; TMR: rho¼ 0.37, P¼ 0.17; SUVmax: rho¼ 0.45,
P¼ 0.09; Spearman’s correlation, two-tailed). Furthermore, the
HVS was significantly associated with CA9 IHC staining (Mann–
Whitney U one-tailed, threshold median of HVS score, P¼ 0.03,
Figure 2B).
To gain some initial insights into potential modes of gene
regulation in tumours with a 64Cu-ATSM imaging hypoxic
phenotype, miRNAs were ranked according to the association of
expression with increasing 64Cu-ATSM hypoxic volume. The top-
ranked genes for association with the hypoxia volume signature
were miR-21-5p (P¼ 0.004, adjusted P¼ 0.99) and miR-10b-5p
(P¼ 0.005, adjusted P¼ 0.99; Figure 2A, Supplementary Table S4).
The study-derived HVS was then inspected in two publicly
available data sets from head and neck cancers with long-term
follow-up and derived from alternative gene expression platforms:
GEO series GSE686 (Chung et al, 2004) and GSE65858
(Wichmann et al, 2015). The genes comprising the HVS were
concordantly expressed within each data set (Supplementary
Figure S6), which indicates that this signature may be widely
relevant to head and neck tumour series. Finally, in exploratory
analyses of each independent series, the HVS was found to be
associated with poorer progression-free survival during a 3-year
follow-up period (GSE65858; HR¼ 1.5 (1.0–2.2), P¼ 0.047), and
there was a suggestive association with worse 3-year recurrence-
free survival (GSE686; HR¼ 3.5 (0.8–16), P¼ 0.1; Supplementary
Figure S6).
DISCUSSION
This study demonstrates that 64Cu-ATSM-defined hypoxic volume
correlates with a previously reported hypoxia gene expression
response and may be an important imaging parameter to consider
for assessment of hypoxia in OPSCCs using PET. In addition, to
describe the gene expression differences that underlie the PET
imaging features, we identified a refined gene signature associated
with 64Cu-ATSM hypoxic volume in OPSCCs.
64Cu-ATSM PET is well tolerated and demonstrates a spectrum
of hypoxic imaging phenotypes in OPSCCs. Cu-ATSM has been
investigated as a promising radiotracer for hypoxia imaging, which
is a challenging area of research as hypoxia is spatially and
temporally heterogeneous. Small clinical studies in HNSCC have
reported that different imaging parameters correlate with progres-
sion or outcome, but there is currently no consensus, and the
molecular mechanisms underlying these associations are not well
understood. In addition, SUVmax, while widely reported, is a single
voxel measure and may be sensitive to technical factors affecting
PET (Adams et al, 2010). Minagawa et al (2011) found that 62Cu-
ATSM SUVmax, but not TMR, was significantly different in 17
locally advanced head and neck cancer patients with and without
residual or recurrent tumours. A study of 25 head and neck cancer
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Figure 2. HVS associated with hypoxic volume. (A) The heatmap displays the HVS, comprising 16 genes positively and 5 genes negatively
associated with hypoxic volume. Samples are ordered by increasing hypoxic volume (base mean 4200; adjusted Po0.05 or (italicised) adjusted
Po0.1). Two genes that overlapped with the 15-gene hypoxia classifier gene list are LOX and PFKFB3. Yellow and blue colour bar shows the
hypoxia 15-gene classifier score by rank within samples, for comparison (Sorensen2015). (B) CA9 IHC is shown compared with ‘low’ or ‘high’ HVS
signature scores for all samples (n¼ 15). ‘High’ is defined as HVS scores greater than the median of HVS scores.
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patients indicated that both increasing SUVmax and TMR were
associated with worse progression-free survival (Sato et al, 2014).
Grassi et al (2014) used 64Cu-ATSM to define a biological target
volume in 11 patients with HNSCC and found this parameter,
along with SUVmax, to have high sensitivity but low specificity in
predicting complete response to therapy. The same group reported
that hypoxic tumour volume and hypoxic burden (hypoxic
tumour volume SUVmean) in 18 patients with lung cancer
or HNSCC were more robust prognostic parameters for progres-
sion-free survival after a median follow-up of 14.6 months (Lopci
et al, 2015), which is in agreement with our data suggesting that
hypoxic volume is an informative feature in 64Cu-ATSM PET
scans. Our data suggest that hypoxic volume might be a more
reliable correlate with gene expression patterns associated with
hypoxia.
The optimal method for volume delineation is uncertain and
requires further investigation. Grassi et al, 2014 used a cutoff of
42% of the lesion SUVmax, but their subsequent study did not apply
a fixed threshold for contouring (Lopci et al, 2015). The limited
spatial resolution of PET makes defining the edge of tumour
uptake difficult and also means that PET imaging does not
necessarily show the microregional, true heterogeneity of hypoxia
within the tumour (Horsman et al, 2012). The mechanism of pO2
dependence and factors that can affect cellular uptake and
retention in both normoxic and hypoxic tissues is also unclear.
Cu-ATSM may be an indirect marker for hypoxia, correlating with
levels of the biological reductants NADH and NADPH (Yoshii
et al, 2012). Hypoxia is one of a number of conditions leading to
NADH accumulation, providing the cellular reduction potential
that leads to tracer retention. Other factors such as multidrug
resistance protein 1 expression (Liu et al, 2009) and CD133þ
expression (Yoshii et al, 2012) have also been shown to influence
Cu-ATSM uptake and retention, as well as cellular copper
metabolism and processing (Hueting et al, 2014). Cu-ATSM is a
promising radiotracer to detect hypoxia, but other possible sources
of uptake need to be taken into consideration when interpreting
the images and determining clinical utility.
We therefore inspected the genes comprising our proposed gene
signature associated with hypoxic volume in OPSCCs. There were
a number of upregulated genes relating to the development of
hypoxia in tumours. For example, SOD2 is an antioxidant enzyme,
which prevents redox-mediated damage of mitochondrial proteins,
and is associated with aggressive cancers with enhanced cell
migration and metastases. Stress such as hypoxia leads to increased
reactive oxygen species (ROS) and tumours may increase their
expression of SOD2 to prevent ROS-mediated DNA damage
(Connor et al, 2007). Also among the upregulated genes, NAMPT
tissue expression has also been found to be upregulated in tumours
and shown to induce cell proliferation and angiogenesis
(Shackelford et al, 2013). It is the rate-limiting enzyme for the
biosynthesis of NAD essential for metabolism and energy
production. Tumour cells have high metabolic rate and NAD
consumption and therefore depend on the production of NAD,
and hypoxia has been shown to result in NAMPT induction (Bae
et al, 2006). NAMPT small-molecule inhibitors are under
investigation as a novel therapeutic, which reduce NAD levels
resulting in ATP loss and inhibition of tumour cell proliferation
(Xu et al, 2015). RUNX3 is downregulated in our samples with
increasing hypoxic volume. RUNX3 has been shown to inhibit
HIF-1a stability through enhancing the interaction between HIF-
1a and PHD2, promoting HIF-1a degradation in gastric cancer
cells (Lee et al, 2014) with resulting inhibition of angiogenesis. Its
expression has been shown to be downregulated in response to
hypoxia and is frequently inactivated in gastric cancer, resulting in
stimulation of proliferation and suppression of apoptosis (Lee et al,
2009). Supplementary Table S5 summarises the genes and their
function.
CA9 is a transmembrane glycoprotein that is induced by
hypoxia and considered an endogenous marker of hypoxia. It is a
downstream target of HIF-1 in the hypoxia response pathway and
has been shown to be overexpressed in HNSCC due to hypoxia
(Beasley et al, 2001). The association between the hypoxic volume
and CA9, and between the 15-gene hypoxia classifier and CA9,
further suggests that hypoxic volume is an important feature for
understanding hypoxic response in this series of OPSCCs and that
the gene expression from FFPE biopsy samples could reflect the
hypoxia response of the tumour.
Among the miRNAs found to be associated with the hypoxic
volume, miR-21 is a frequently dysregulated miRNAs in HNSCC
(Chang et al, 2008). Upregulation of miR-21 promotes cell
proliferation, migration and inhibition of apoptosis and is
associated with poor prognosis (Lu et al, 2008). Mir-210, the
hypoxia miRNA (Huang et al, 2010), had low base coverage in
our analysis and was not associated with hypoxia expression
signatures.
This study had several limitations. First, there was a small
sample size that is typical of exploratory imaging-genomic studies
with patients recruited from a single institution. However, a strong
point of our study is that the PET studies were performed and
analysed in a standardised way at a single PET centre. Second, the
validation of our hypoxia-associated signature was limited to in
silico functional investigations in the absence of a clinical validation
set and warrants further study to elucidate the mechanisms
underlying these associations. Third, Cu-ATSM as a radiotracer
provides hypoxic-to-normoxic contrast of sufficient quality to
define a hypoxic volume but the optimal method for hypoxic
volume delineation requires further investigation. Owing to the
existing clinical protocols for obtaining biopsy samples, it was not
possible to attempt any registration (alignment) of biopsy sites and
PET scans. Hypoxia responses detected in the diagnostic biopsy
(CA9 hypoxia biomarker and gene expression profiling) were used
to indicate the hypoxic status of the tumour and more directly
reflects clinical practice. These factors may be considered a
limitation, and although outside the scope of this study, further
work is needed to understand the effect of tumour heterogeneity
on hypoxia evaluation in OPSCCs.
In conclusion, by combining PET imaging and mRNA
expression profiling, our study revealed that Cu-ATSM PET
hypoxic volume is associated with hypoxia gene signatures in
OPSCCs and suggests that PET could be a useful surrogate for
hypoxia gene signatures in order to stratify patients for treatment.
As with all exploratory biomarker studies, our findings now require
prospective investigation in a larger number of patients.
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